Organovo Holdings, Inc. is an early commercial-stage company focused on developing and commercializing functional human tissues. The Company focuses on the generation of three-dimensional (3D) human tissues, by utilizing its platform technology to create human tissue constructs in 3D. It is focused on development of products, including 3D human tissues used for the preclinical assessment of drug effects, including applications in predictive toxicology, absorption, distribution, metabolism, excretion (ADME), and drug metabolism and pharmacokinetics (DMPK); customized human tissues as living, dynamic models of human biology or disease, for use in drug discovery and development, and three-dimensional human tissues for clinical applications, such as blood vessels for bypass grafting, nerve grafts for nerve damage repair and functional tissue patches for the repair or replacement of damaged tissues and organs.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Biotechnology & Medical Research
- Sub-Industry: N/A
- Symbol: AMEX:ONVO
- CUSIP: N/A
- Web: organovo.com/
- 50 Day Moving Avg: $2.08
- 200 Day Moving Avg: $2.61
- 52 Week Range: $1.75 - $4.18
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -5.47
- P/E Growth: 0.00
- Annual Revenue: $4.33 million
- Price / Sales: N/A
- Book Value: $0.54 per share
- Price / Book: 3.65
- EBIDTA: ($38,770,000.00)
- Net Margins: -1,020.40%
- Return on Equity: -67.74%
- Return on Assets: -61.91%
- Average Volume: 807,516 shs.
- Short Ratio: 21.68
Frequently Asked Questions for Organovo Holdings (AMEX:ONVO)
What is Organovo Holdings' stock symbol?
Organovo Holdings trades on the AMEX under the ticker symbol "ONVO."
Where is Organovo Holdings' stock going? Where will Organovo Holdings' stock price be in 2017?
2 analysts have issued twelve-month target prices for Organovo Holdings' shares. Their predictions range from $3.75 to $3.75. On average, they expect Organovo Holdings' share price to reach $3.75 in the next year. View Analyst Ratings for Organovo Holdings.
Who are some of Organovo Holdings' key competitors?
Some companies that are related to Organovo Holdings include Agenus (AGEN), Arbutus Biopharma Corporation (ABUS), Idera Pharmaceuticals (IDRA), Corvus Pharmaceuticals (CRVS), Concert Pharmaceuticals (CNCE), NewLink Genetics Corporation (NLNK), Celldex Therapeutics (CLDX), Novavax (NVAX), Puretech Health PLC (PRTC), Protagonist Therapeutics (PTGX), Codexis (CDXS), Curis (CRIS), Nabriva Therapeutics AG (NBRV), Horizon Discovery Group PLC (HZD), Merrimack Pharmaceuticals (MACK), Advaxis (ADXS), Compugen (CGEN) and Chromadex Corp (CDXC).
Who are Organovo Holdings' key executives?
Organovo Holdings' management team includes the folowing people:
- Taylor J. Crouch, President, Chief Executive Officer
- Eric Michael David M.D. J.D., Executive Vice President - Pre-Clinical Development, Chief Strategy Officer
- Sharon Collins Presnell Ph.D., Chief Scientific Officer
- Jennifer Kinsbruner Bush J.D., Compliance Officer, General Counsel, Corporate Secretary
- Paul Gallant, General Manager
- Richard Maroun, Director
- Robert F. Baltera Jr., Lead Independent Director
- James T. Glover, Independent Director
- Richard A. Heyman Ph.D., Independent Director
- Tamar D. Howson, Independent Director
How do I buy Organovo Holdings stock?
Shares of Organovo Holdings can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Organovo Holdings' stock price today?
MarketBeat Community Rating for Organovo Holdings (AMEX ONVO)MarketBeat's community ratings are surveys of what our community members think about Organovo Holdings and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Organovo Holdings stock can currently be purchased for approximately $1.97.
Consensus Ratings for Organovo Holdings (AMEX:ONVO) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||2 Buy Ratings|
|Consensus Rating:||Buy (Score: 3.00)|
|Consensus Price Target: ||$3.75|
Analysts' Ratings History for Organovo Holdings (AMEX:ONVO)
(Data available from 9/24/2015 forward)
|6/12/2017||Evercore ISI||Lower Price Target||Outperform||$4.00 -> $3.75|
|1/25/2017||Raymond James Financial, Inc.||Initiated Coverage||Outperform|
Earnings History for Organovo Holdings (AMEX:ONVO)
No earnings announcements for this company have been tracked by MarketBeat.com
Earnings Estimates for Organovo Holdings (AMEX:ONVO)
Current Year EPS Consensus Estimate: $-0.39 EPS
Next Year EPS Consensus Estimate: $-0.36 EPS
Dividend History for Organovo Holdings (AMEX:ONVO)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Organovo Holdings (AMEX:ONVO)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for Organovo Holdings (AMEX:ONVO)
Latest Headlines for Organovo Holdings (AMEX:ONVO)
|Here's Why Organovo Holdings Inc Fell 10.5% in June|
www.fool.com - July 10 at 11:29 AM
|Organovo Holdings, Inc. :ONVO-US: Earnings Analysis: Q4, 2017 By the Numbers : June 13, 2017|
finance.yahoo.com - June 13 at 10:37 AM
|Evercore ISI Lowers Organovo Holdings Inc (ONVO) Price Target to $3.75|
www.americanbankingnews.com - June 12 at 3:38 PM
|Organovo Announces Fiscal Fourth-Quarter and Full-Year 2017 Results; Company Issues Full-Year Fiscal 2018 Outlook|
finance.yahoo.com - June 7 at 6:52 PM
|Organovo reports 4Q loss|
finance.yahoo.com - June 7 at 6:52 PM
|3 Stocks That Could Put Amazon.com's Returns to Shame|
finance.yahoo.com - May 24 at 10:14 AM
|EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit Against Intra-Cellular Therapies, Inc. - ITCI|
www.thestreet.com - May 13 at 12:47 AM
|Organovo Holdings, Inc. breached its 50 day moving average in a Bullish Manner : ONVO-US : May 2, 2017|
finance.yahoo.com - May 2 at 11:11 AM
|Organovo Collaborates With University of Virginia to Develop Bioprinted Tissues for Volumetric Muscle Loss Injury|
finance.yahoo.com - May 1 at 12:04 PM
|Organovo Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)|
finance.yahoo.com - April 24 at 5:51 PM
|Why Organovo Holdings Inc Shareholders Have Something to Worry About|
www.fool.com - April 18 at 5:48 PM
|BRIEF-Organovo reports CEO transition|
www.reuters.com - April 11 at 6:55 PM
|What's Next for Organovo Holdings Inc.?|
finance.yahoo.com - April 11 at 10:43 AM
|What's Next for Organovo Holdings Inc.?|
www.fool.com - April 11 at 7:30 AM
|Organovo (ONVO) Publishes Data Describing Physiology of 3D Bioprinted Human Kidney Tissues for Drug Toxicity Testing|
www.streetinsider.com - February 21 at 5:50 PM
|Organovo Holdings' Unpleasant Q3 Surprise: Still Plenty of Skepticism About 3D Tissues|
www.fool.com - February 10 at 1:10 AM
|Organovo Holdings Inc Earnings Call (Q3 2017)|
biz.yahoo.com - February 9 at 1:01 AM
|Coverage initiated on Organovo by Raymond James|
finance.yahoo.com - January 25 at 5:25 PM
|The Possible Reason Behind Organovo Holdings, Inc.'s Big Climb in April|
www.fool.com - May 5 at 10:38 AM
|3 Ways Technology Is Set to Change the Face of Healthcare|
www.fool.com - March 19 at 9:04 AM
|Organovo (ONVO) Announces Presentations of exVive3DTM Human Liver Model Data at SOT Annual Meeting|
www.streetinsider.com - March 10 at 11:49 AM
|Organovo and Its Customers Present Data Supporting 3D Bioprinted Liver Tissues for Drug Toxicity Testing and Liver Fibrosis Modeling|
finance.yahoo.com - March 10 at 8:05 AM
|5 Key Takeaways from Organovo Holdings Inc.'s Investor Conference|
www.fool.com - February 12 at 2:42 PM
|ORGANOVO HOLDINGS, INC. Financials|
finance.yahoo.com - February 12 at 1:04 PM
|Organovo Announces Fiscal Third-Quarter Results; Company Updates Full-Year Fiscal 2016 Outlook and Affirms Long-Range Guidance|
finance.yahoo.com - February 8 at 4:10 PM
|ORGANOVO HOLDINGS, INC. Files SEC form 10-Q, Quarterly Report|
biz.yahoo.com - February 8 at 4:09 PM
|What's Going on With Organovo Holdings, Inc.?|
www.fool.com - January 22 at 8:40 AM
|ORGANOVO HOLDINGS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhib|
biz.yahoo.com - January 19 at 8:06 AM
|8:06 am Organovo: CFO Barry Michaels to retire at end of fiscal year|
finance.yahoo.com - January 19 at 8:06 AM